Literature DB >> 10459140

Acitretin in psoriasis: an overview of adverse effects.

H I Katz1, J Waalen, E E Leach.   

Abstract

Oral retinoids are among the drugs of choice for pustular and erythrodermic psoriasis. In addition, retinoids are effective in combination with other topical and systemic agents for the treatment of plaque-type psoriasis. Acitretin, the active retinoid metabolite, has replaced etretinate in retinoid therapy of psoriasis because of its more favorable pharmacokinetic profile, including a significantly shorter half-life. Retinoids, including acitretin, are potent teratogens, leading to strict requirements for pregnancy prevention during and after their use. Other retinoid side effects are generally preventable or manageable through proper patient selection, dose adjustments, and routine monitoring. Mucocutaneous side effects such as cheilitis and hair loss are the most common dose-dependent side effects, requiring dose reduction in some patients. Less common effects such as hepatotoxicity, serum lipid alterations, pancreatitis, and possible skeletal effects are also discussed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10459140     DOI: 10.1016/s0190-9622(99)70359-2

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  21 in total

1.  Rapid improvement of chronic interstitial keratitis with acitretin.

Authors:  M Labetoulle; H Offret; I Bournerias; E Frau
Journal:  Br J Ophthalmol       Date:  2002-12       Impact factor: 4.638

2.  Cystoid macular edema associated with acitretin.

Authors:  Joel Yap; Alex Buller
Journal:  Digit J Ophthalmol       Date:  2013-12-30

Review 3.  Comparative tolerability of systemic treatments for plaque-type psoriasis.

Authors:  Stacy L McClure; Jayme Valentine; Kenneth B Gordon
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

4.  Association between Psoriasis and Cardiovascular Risk Factors in Korean Patients.

Authors:  Woo Jin Choi; Eun Joo Park; In Ho Kwon; Kwang Ho Kim; Kwang Joong Kim
Journal:  Ann Dermatol       Date:  2010-08-05       Impact factor: 1.444

5.  Psoriasis and cardiovascular disorders: association or epiphenomenon? Meta-analysis of observational studies.

Authors:  Saumya Choudhary; Rachana Patel; Dibyabhaba Pradhan; Ravi Deval; Harpreet Singh; George Thomas; Arun Kumar Jain
Journal:  3 Biotech       Date:  2020-02-07       Impact factor: 2.406

6.  Pivotal role of Acitretin nanovesicular gel for effective treatment of psoriasis: ex vivo-in vivo evaluation study.

Authors:  Irhan Ibrahim Abu Hashim; Noha Fawzy Abo El-Magd; Ahmed Ramadan El-Sheakh; Mohammed Fawzy Hamed; Abd El-Gawad Helmy Abd El-Gawad
Journal:  Int J Nanomedicine       Date:  2018-02-20

7.  Acitretin-associated erectile dysfunction: a case report.

Authors:  Marco Rossi; Michele Pellegrino
Journal:  Cases J       Date:  2009-11-19

8.  Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis.

Authors:  C Leonardi; A Menter; T Hamilton; I Caro; B Xing; A B Gottlieb
Journal:  Br J Dermatol       Date:  2008-03-27       Impact factor: 9.302

9.  Assessment by HPLC of the degradation behavior of acitretin under hydrolytic, oxidative, photolytic and thermal stress conditions.

Authors:  Pawan K Porwal; Neeraj Upmanyu
Journal:  Acta Pharm Sin B       Date:  2014-10-07       Impact factor: 11.413

10.  The Risk of Chronic Pancreatitis in Patients with Psoriasis: A Population-Based Cohort Study.

Authors:  Hsien-Yi Chiu; Chi-Feng Hsieh; Yi-Ting Chiang; Weng-Foung Huang; Tsen-Fang Tsai
Journal:  PLoS One       Date:  2016-07-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.